Abstract
Background: Ginkgo biloba extract EGb761 has shown the neuroprotective effects on Alzheimer's disease (AD) through the protection against the Aβ-induced neurotoxicity. However, it is not completedly clear whether EGb761 attenuates tau hyperphosphorylation, another of the most prominent mechanisms underlying the pathology of AD.
Methods: we employed hyperhomocysteinemia (HHcy) to mimic AD like pathological alterations and memory deficits in rats as model, and injected EGb761 with or after HHcy injection as prevention and treatment, injected saline as control. We measured the status of oxidative damage and spatial and learning memory in rats. Then we detected the level of memory-related proteins, tau phosphorylation and the level and activity of tau kinase (GSK-3β) and phosphatase (PP2A) by Western blotting and Immunohistochemistry.
Results: We found that EGb761 could significantly antagonize HHcy-induced oxidative damage, recover PP2Ac and GSK3β activities deregulated by HHcy. Furthermore, tau was hyperphosphorylated at Thr231, Ser262, Ser396, and Ser404, most common PP2Ac and GSK3β targeted sites in the hippocampus and prefrontal cortex of HHcy rats, whereas EGb761 recovered the tau phosphorylation at those sites. Behavioral tests revealed that EGb761 rescued HHcy-induced spatial reference memory deficit and upregulated the expression of synapse-associated protein PSD95 and synapsin-1.
Conclusion: EGb761 might be a promising drug to treat AD through its anti-oxidative activity and decreasing tau hyperphosphorylation besides the protection against the Aβ-induced neurotoxicity.
Keywords: Ginkgo biloba extract EGb761, Alzheimer's disease (AD), hyperhomocysteinemia (HHcy), tau hyperphosphorylation, cognitive impairment, oxidative damage.
Current Alzheimer Research
Title:Ginkgo biloba Extract EGb761 Attenuates Hyperhomocysteinemia-induced AD Like Tau Hyperphosphorylation and Cognitive Impairment in Rats
Volume: 15 Issue: 1
Author(s): Kuan Zeng, Mengzhu Li, Jichang Hu, Yacoubou Abdoul Razak Mahaman, Jian Bao, Fang Huang, Yiyuan Xia, Xinghua Liu, Qun Wang, Jian-Zhi Wang, Yang Yang, Rong Liu and Xiaochuan Wang*
Affiliation:
- Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Ministry of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030,China
Keywords: Ginkgo biloba extract EGb761, Alzheimer's disease (AD), hyperhomocysteinemia (HHcy), tau hyperphosphorylation, cognitive impairment, oxidative damage.
Abstract: Background: Ginkgo biloba extract EGb761 has shown the neuroprotective effects on Alzheimer's disease (AD) through the protection against the Aβ-induced neurotoxicity. However, it is not completedly clear whether EGb761 attenuates tau hyperphosphorylation, another of the most prominent mechanisms underlying the pathology of AD.
Methods: we employed hyperhomocysteinemia (HHcy) to mimic AD like pathological alterations and memory deficits in rats as model, and injected EGb761 with or after HHcy injection as prevention and treatment, injected saline as control. We measured the status of oxidative damage and spatial and learning memory in rats. Then we detected the level of memory-related proteins, tau phosphorylation and the level and activity of tau kinase (GSK-3β) and phosphatase (PP2A) by Western blotting and Immunohistochemistry.
Results: We found that EGb761 could significantly antagonize HHcy-induced oxidative damage, recover PP2Ac and GSK3β activities deregulated by HHcy. Furthermore, tau was hyperphosphorylated at Thr231, Ser262, Ser396, and Ser404, most common PP2Ac and GSK3β targeted sites in the hippocampus and prefrontal cortex of HHcy rats, whereas EGb761 recovered the tau phosphorylation at those sites. Behavioral tests revealed that EGb761 rescued HHcy-induced spatial reference memory deficit and upregulated the expression of synapse-associated protein PSD95 and synapsin-1.
Conclusion: EGb761 might be a promising drug to treat AD through its anti-oxidative activity and decreasing tau hyperphosphorylation besides the protection against the Aβ-induced neurotoxicity.
Export Options
About this article
Cite this article as:
Zeng Kuan , Li Mengzhu, Hu Jichang , Mahaman Abdoul Razak Yacoubou , Bao Jian , Huang Fang , Xia Yiyuan, Liu Xinghua , Wang Qun, Wang Jian-Zhi , Yang Yang, Liu Rong and Wang Xiaochuan *, Ginkgo biloba Extract EGb761 Attenuates Hyperhomocysteinemia-induced AD Like Tau Hyperphosphorylation and Cognitive Impairment in Rats, Current Alzheimer Research 2018; 15 (1) . https://dx.doi.org/10.2174/1567205014666170829102135
DOI https://dx.doi.org/10.2174/1567205014666170829102135 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Cancer-Homing Toxins
Current Pharmaceutical Design Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry A Current Review of Cypermethrin-Induced Neurotoxicity and Nigrostriatal Dopaminergic Neurodegeneration
Current Neuropharmacology Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Illuminating microRNA Transcription from the Epigenome
Current Genomics Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses
Current Drug Targets - CNS & Neurological Disorders Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Golgi Localization of Glycosyltransferases Involved in Ganglioside Biosynthesis
Current Drug Targets A Review on Melatonin’s Effects in Cancer: Potential Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Amino Acid Degrading Enzymes and their Application in Cancer Therapy
Current Medicinal Chemistry Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design